
SOHO Insider editors on 2026 highlights in blood cancers
As 2026 comes to a close, the SOHO Insider editors reflect on this year’s news in blood cancers.
The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

As 2026 comes to a close, the SOHO Insider editors reflect on this year’s news in blood cancers.

In this video, which is part of an educational series on myelodysplastic syndromes with SOHO young investigators, Rami Komrokji, MD, leads a discussion on risk stratification and clinical decision-making in MDS, including the use of IPSS-R and IPSS-M, treatment strategies and the timing of stem cell transplantation.

Julie Braish, MD, a fellow at Moffitt Cancer Center, discusses a retrospective study to determine if durable complete remission, defined as lasting at least six months, could be predicted using baseline clinical and molecular characteristics in patients with higher-risk myelodysplastic syndromes.

In validation testing, the assays showed 96.3% sensitivity and 98.2% specificity for identifying CLL. Designed as a ready-to-use system that replaces manual liquid reagent cocktails, the workflow combines reagents, staining protocols, and assay templates to cut manual preparation steps by 95%.

The study evaluated the safety profile and hospital resource utilization of caplacizumab in a largely geriatric patient cohort. Researchers compared patients who received caplacizumab alongside standard plasmapheresis and rituximab against those who received plasmapheresis and rituximab alone.

The study enrolled 236 patients with Ph–positive ALL and randomized 158 to ponatinib plus blinatumomab and 78 to imatinib plus chemotherapy as frontline therapy. The cohort had a median age of 55 years range, 24-82. Patients in the control group who had persistent disease or measurable residual disease reappearance were allowed to crossover to ponatinib plus blinatumomab.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
Submit your difficult clinical questions to the Ask-the-Expert forum in the SOHO mobile app. Submit your questions in our exclusive members-only forums community on the SOHO mobile app. Your inquiry will be sent directly to leading experts, including Dr. Hagop Kantarjian, Dr. Kami Maddocks, Dr. Sagar Lonial, and Dr. Mascarenhas for their insights.
Follow the instructions below to ask a question now!
Benefits of membership include:
The Career Center provides SOHO members with the ability to find jobs in the field of Hematologic Oncology along with a variety of career advice. Select the 'Career Center' button to explore new job opportunities and career information.
The Career Center Allows SOHO Members to:
To access the SOHO Career Center click the following link.